Advertisement
Advertisement
U.S. markets open in 3 hours 24 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Celsion Corporation (CLSN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.54000.0000 (0.00%)
At close: 04:00PM EDT
2.6000 +0.06 (+2.36%)
After hours: 05:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close2.5400
Open2.4800
Bid2.5000 x 900
Ask0.0000 x 800
Day's Range2.3700 - 2.6742
52 Week Range1.8000 - 17.7000
Volume202,623
Avg. Volume64,779
Market Cap18.031M
Beta (5Y Monthly)2.30
PE Ratio (TTM)N/A
EPS (TTM)-3.9680
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CLSN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Celsion Corporation
    Rating decreased to a HOLDALEXION PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $202.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

    LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 177,000 shares of common stock, and (ii) restricted stock grants (the "Inducement Stock Grants") totaling 53,000 shares of commo

  • GlobeNewswire

    Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

    Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company’s Board of Directors has appointed biopharmaceutical leader Corinne Le Goff, Pharm D, MBA, as President and Chief Executive Officer and Director, effective July 18, 2022. Current President and CEO Michael H. Tardugno will co

  • GlobeNewswire

    Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

    NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3nbZJuOThe company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accepting 1x1 manag

Advertisement
Advertisement